The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists
In recent years, peroxisome proliferator-activated receptor gamma (PPARγ) has been reported to be a target for the treatment of type II diabetes. Furthermore, it has received attention for its therapeutic potential in many other human diseases, including atherosclerosis, obesity, and cancers. Recent...
Saved in:
Main Author: | Tamotsu Tsukahara |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | PPAR Research |
Online Access: | http://dx.doi.org/10.1155/2012/362361 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia
by: Sarawin Harnchoowong, et al.
Published: (2017-01-01) -
Identification of Bexarotene as a PPARγ Antagonist with HDX
by: David P. Marciano, et al.
Published: (2015-01-01) -
PPARγ and Its Agonists in Chronic Kidney Disease
by: Yuhua Ma, et al.
Published: (2020-01-01) -
Mechanisms Mediating the Effects of γ-Tocotrienol When Used in Combination with PPARγ Agonists or Antagonists on MCF-7 and MDA-MB-231 Breast Cancer Cells
by: Abhita Malaviya, et al.
Published: (2013-01-01) -
New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy
by: Zhanjun Jia, et al.
Published: (2014-01-01)